Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026C-FORWARD ...
Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
The Daily of the University of Washington

‘Hep C Free Washington’ initiative correlated with reduced treatment costs

A recent study by UW researchers found that the 2019 “Hep C Free Washington” initiative was correlated with a decrease in the ...
Medscape

Drop in HIV/HCV Coinfections After Nationwide HCV Program

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Seeking Alpha

Atea targets mid-2026 Phase III HCV results while expanding hepatitis pipeline and maintaining $329.3M cash runway

Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...
Nasdaq

Atea Pharmaceuticals Advances HCV Treatment with Ongoing Phase 3 C-BEYOND Trial and Promising Phase 2 Results for Bemnifosbuvir and Ruzasvir at EASL 2025

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
Healio

‘Data are sobering’: Antiviral prescriptions for HCV drop by nearly 66% since 2015

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Annual courses of direct-acting antivirals for HCV have ...
MedPage Today

Jail-Based HCV Testing, Treatment May Deliver Substantial Community Returns

Injection drug use is both a potent risk factor for incarceration and the primary transmission route for hepatitis C virus (HCV) infections. Combining HCV testing and treatment in jails with ...